A randomized controlled trial comparing continuous and as-required XXXX use during screening colonoscopy.

@entity1 @entity1296 @entity26 @entity158 @entity3810
BACKGROUND AND STUDY AIMS: Entonox is a 50   :   50 combination of @entity3810 and @entity26 , which may be used to manage @entity158 during colonoscopy. The optimal mode of Entonox administration is unknown. The aim of this study was therefore to compare continuous and as-required Entonox use. @entity1 AND METHODS: @entity1 attending for screening colonoscopy at a single centre were randomized to continuous or as-required Entonox use. The primary outcome measure was the @entity1 's overall @entity158 rating at the time of discharge (verbally administered numerical ratings scale, 0=no @entity158 and 10=extreme @entity158 ). Secondary outcome measures included the @entity1 ' experience of @entity158 during the colonoscopy (rated every 2   min), side effects and the need for rescue intravenous medications. RESULTS: A total of 108 @entity1 were randomized, and 100 completed the study (46 continuous, 54 as required). The overall @entity158 scores at discharge did not differ between those who used Entonox continuously and as required (mean=2.4 vs. 3.2, P=0.08). There were also no differences in the experience of @entity158 during colonoscopy (mean=1.8 vs. 2.2, P=0.28; peak=4.2 vs. 4.8, P=0.26; and area under curve=23 vs. 30, P=0.24). @entity1 with high anxiety had greater overall @entity158 scores (mean=3.7 vs. 2.4, P=0.03). Light @entity1296 occurred more often with continuous Entonox use (48 vs. 21%, P=0.009). CONCLUSION: Among @entity1 attending for screening colonoscopy, comfort ratings were similar in those using Entonox continuously and as required, but light @entity1296 was more common with continuous use (NCT identifier: 01865721).
